Table 6.5 Understanding the New Roles in the Life Sciences Industry

Table 6.5 Understanding the New Roles in the Life Sciences Industry

New Role	Why This Role Is Emerging (Key Drivers)	Where in Life Sciences (Segments) It Applies	Key Skills Needed / Description
AI drug discovery platform architect	GenAI + machine learning + digital biology platforms accelerating target identification and lead optimisation	Pharma, biotech, contract research organisations	Builds/owns AI-driven discovery stack; needs biology + machine learning + cloud architecture knowledge
Digital trial and decentralised study manager	Rise of remote/hybrid trials, wearables, real-world data capture	Clinical development, contract research organisations, pharma	Manages virtual/hybrid trial platforms; skills in telemedicine, remote monitoring, data integrity
Bioprocess automation and digital manufacturing engineer	Smart/continuous manufacturing, biologics scale-up, IIoT	Biologics manufacturing, pharma manufacturing, contract manufacturing	Designs digital workflows, automates bioprocess; needs bioprocess + automation + data analytics
Ethical AI and autonomous systems auditor (life sciences)	Use of AI in drug/test design, autonomous labs

need for governance, explainability

R&D, discovery labs, biotech
• Assesses AI systems and ensures compliance and ethics
• Needs AI governance, regulatory understanding, bio-domain knowledge

Industrial biomanufacturing process developer
Synthetic biology, biomanufacturing of chemicals/therapies
Biotech, life sciences manufacturing
• Develops bio-based manufacturing methods
• Skills in fermentation, bioprocess, scale-up, sustainability

Real-world evidence & omics integration lead
Huge growth in omics + electronic health records + real-world data for regulatory/commercial use
Pharma, regulatory affairs, market access
• Integrates genomics/proteomics + patient data
• Needs data science + clinical/biologic domain + regulatory knowledge

Digital trust & consent steward (life sciences)
Data privacy, patient consent, cross-border data flows (DPDP/GDPR and so on)
Digital health, clinical development, biotech
• Manages consent frameworks, vendor risk, data governance
• Needs privacy law, data architecture, stakeholder management

Industrial data marketplace product owner (life sciences)
Machine/clinical/omics data monetisation, ecosystem platforms
Pharma, Biotech, MedTech
• Builds data monetisation platforms, API ecosystems
• Requires product management, data economics, domain context

Human-digital collaboration experience designer (lab/clinic)
Labs/clinics becoming smart, need UX for digital-biology + human workflows
Discovery labs, clinical sites, MedTech
• Designs experience for scientists/clinicians using AI/automation
• Needs UX, change management, domain fluency

Carbon & circular biomanufacturing lead
Sustainability, circular biology, bioeconomy demands
Manufacturing, biotech, pharma
• Designs low-carbon manufacturing, material loops, circular processes
• Skills in sustainability, bioengineering, process design

Leadership Imperatives for the Life Sciences Industry in the AI Era

While many entities in the life sciences industry have started training the workforce and planning for the emerging roles in the AI era, more than ever before, leaders have to actively lead, encourage and facilitate partnerships between academia, bioinformatics specialist firms and AI solution providers as the data from various partners would need to be brought together for building AI models. Data streams would include other sources as well, for example, omics, wearables and multiple types and categories of healthcare providers who would be bound by their own agreements with their customers. Leaders have to brace themselves to not only champion AI-led drug discovery processes and scientific integrity but also develop clarity for complex questions related to data ownership and accountability. Furthermore, leaders would need to develop innovative strategies to build cross-industry bridges like the case of ABB and Thermo Fisher blending process engineering capabilities with biopharma analytics. Institutionalising AI-led adaptive trial designs, patient monitoring and ethical governance would require the attention of leaders. Investment in automation, drug release timing and regulatory compliance would be an ongoing balancing act for leaders. All of this would pose another significant challenge to be addressed by the leaders: that of ownership of innovation, outcomes and intellectual property. Table 6.6 provides the detailed outline of how leadership in the AI era would evolve in the life sciences industry.

Table 6.6 Leadership Imperatives for the Life Sciences Industry: Traditional vs AI Era

Dimension
Traditional Life Sciences Leadership
AI-Era Life Sciences Leadership

Core leadership focus
Discovery and safety through scientific rigour and compliance; long R&D cycles with limited integration across teams
• Speed, precision and ethical innovation powered by AI
• Real-time collaboration across discovery, clinical, manufacturing and patient ecosystems

Leadership philosophy
Science-led, cautious, hierarchical; success measured by accuracy, approvals and incremental innovation
• Data-led, agile and collaborative
• Success measured by discovery velocity, ethical AI use and patient outcomes

Leadership style
Expert-centric and authority-driven; decisions made by senior scientists and clinicians
• Networked and cross-disciplinary
• Leaders integrate data scientists, clinicians, ethicists and technologists

Decision-making model
Sequential, hypothesis-driven, reliant on manual experimentation and retrospective analysis
• Non-linear, simulation-driven, using predictive modelling, GenAI and in-silico validation

R&D and discovery leadership
Based on lab experiments, trial-and-error molecule design and lengthy human trials
• AI-enabled drug discovery and clinical simulation
• Leaders oversee hybrid teams of biologists and AI modellers

Clinical trials & evidence generation
Dependent on physical recruitment, site monitoring and manual data logging
• Adaptive, decentralised trials using AI for patient selection, outcome prediction and synthetic control groups

Data & technology use
Fragmented lab and patient data; limited computational power; siloed bioinformatics
• Integrated AI pipelines combining omics, electronic health records, imaging and real-world data for continuous insight generation

Regulatory leadership
Compliance after experimentation;

reactive responses to audits and changing regulations

•Proactive compliance with continuous monitoring, explainable AI and algorithmic traceability built into the workflow

Ethical orientation

Ethical oversight confined to human and animal testing norms

•Expanded ethical mandate covering algorithmic bias, genomic privacy, consent and equitable access to AI-enabled therapies

Innovation leadership

Dependent on serendipitous discoveries and incremental lab breakthroughs

•Systematic, data-driven innovation via generative design, knowledge graphs and AI-assisted hypothesis generation

Manufacturing leadership

Batch-based, manual quality assurance and reactive error correction

•AI-driven continuous manufacturing

•Predictive quality control and ‘right-first-time’ production guided by data analytics

Organisational structure

Vertical and function-based: R&D, clinical, regulatory and marketing operated independently

•Horizontal and integrated: cloud-connected platforms link research, production, compliance and patient engagement

Leadership competencies

Scientific expertise, regulatory understanding, risk aversion and perseverance

•Data literacy, ethical foresight, interdisciplinary agility and digital transformation vision

Talent & workforce leadership

Focused on laboratory scientists, clinicians and regulatory specialists

•Blended teams of biologists, data scientists, AI engineers, ethicists and patient experience designers

Patient engagement

Transactional—patients as trial participants or end users

•Relational—patients as data partners

•AI enables continuous feedback and personalised care pathways

Collaboration ecosystem

Partnerships limited to academia, contract research organisations and government funding bodies

•Open innovation networks involving cloud providers, AI start-ups, universities and health systems

Risk & governance

Managed via documentation and periodic audits; low tolerance for failure

•Managed through real-time AI dashboards; leaders embrace agile experimentation while upholding ethical and regulatory guard rails

Sustainability & access

Global access and affordability often secondary to profitability

•AI supports equitable healthcare delivery, local manufacturing and personalized medicine

•Leaders link ESG to social innovation

Metrics of success

Number of drugs approved, patents filed, regulatory compliance

•Time-to-discovery, patient outcomes, data transparency and ecosystem impact